Prosthetic Joint Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by 
All the vital news, analysis, and commentary curated by our industry experts.
PJI Pipeline Products Market Report Overview
Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue, and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus, and advanced HIV disease. Treatment includes antimicrobial therapy.
The PJI pipeline market research report provides comprehensive information on the therapeutics under development for PJI, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for PJI and features dormant and discontinued projects.
PJI Pipeline Products Market Segmentation by Targets
The key targets in the PJI pipeline products market are Bacterial Cell Wall, 16S Ribosomal RNA, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial, DNA Gyrase, DNA Topoisomerase IV, RNA Polymerase, and Staphylococcus aureus Bifunctional Autolysin. The Bacterial Cell Wall is the leading target in the pipeline.
PJI Pipeline Products Market Analysis by Targets
For more target insights into the PJI pipeline products market, download a free report sample
PJI Pipeline Products Market Segmentation by Mechanisms of Action
The key mechanisms of action in the PJI pipeline products market are Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial Activator, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, RNA Polymerase Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor. Bacterial Cell Wall Disruptor is the leading MoA in the pipeline market.
PJI Pipeline Products Market Analysis by Mechanisms of Action
For more mechanisms of action insights into the PJI pipeline products market, download a free report sample
PJI Pipeline Products Market Segmentation by Routes of Administration
The key routes of administration in the PJI pipeline products market are intravenous, intraarticular, parenteral, oral, and topical. Intravenous is the leading RoA.
PJI Pipeline Products Market Analysis by Routes of Administration
For more routes of administration insights into the PJI pipeline products market, download a free report sample
PJI Pipeline Products Market Segmentation by Molecule Types
The key molecule types in the PJI pipeline products market are biologic, small molecule, recombinant enzyme, monoclonal antibody, and synthetic peptide. Biologic is the leading molecule type.
PJI Pipeline Products Market Analysis by Molecule Types
For more molecule type insights into the PJI pipeline products market, download a free report sample
PJI Pipeline Products Market - Competitive Landscape
Some of the leading companies in the PJI pipeline products market are ContraFect Corp, Adaptive Phage Therapeutics Inc, Arietis Corp, Armata Pharmaceuticals Inc, Integrated BioTherapeutics Inc, Lumobiotics GmbH, Osteal Therapeutics Inc, Peptilogics Inc, and Pherecydes Pharma SA among others. ContraFect Corp is the leading company in the PJI pipeline products market.
PJI Pipeline Products Market Analysis by Companies
To know more about the leading players in the PJI pipeline products market, download a free report sample
PJI Pipeline Products Market Report Overview
| Key Targets | Bacterial Cell Wall, 16S Ribosomal RNA, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial, DNA Gyrase, DNA Topoisomerase IV, RNA Polymerase, and Staphylococcus aureus Bifunctional Autolysin |
| Key Mechanisms of Action | Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial Activator, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, RNA Polymerase Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor |
| Key Routes of Administration | Intravenous, Intraarticular, Parenteral, Oral, and Topical |
| Key Molecule Type | Biologic, Small Molecule, Recombinant Enzyme, Monoclonal Antibody, and Synthetic Peptide |
| Leading Companies | ContraFect Corp, Adaptive Phage Therapeutics Inc, Arietis Corp, Armata Pharmaceuticals Inc, Integrated BioTherapeutics Inc, Lumobiotics GmbH, Osteal Therapeutics Inc, Peptilogics Inc, and Pherecydes Pharma SA |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of PJI.
- The pipeline guide reviews pipeline therapeutics for PJI by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in PJI therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates PJI therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for PJI
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for PJI.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding the PJI pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Arietis Corp
Armata Pharmaceuticals Inc
ContraFect Corp
Integrated BioTherapeutics Inc
Lumobiotics GmbH
Osteal Therapeutics Inc
Peptilogics Inc
Pherecydes Pharma SA
Qentoros Inc
Sonoran Biosciences Inc
TenNor Therapeutics Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key targets in the PJI pipeline products market?
The key targets in the PJI pipeline products market are Bacterial Cell Wall, 16S Ribosomal RNA, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial, DNA Gyrase, DNA Topoisomerase IV, RNA Polymerase, and Staphylococcus aureus Bifunctional Autolysin.
-
What are the key mechanisms of action in the PJI pipeline products market?
The key mechanisms of action in the PJI pipeline products market are Bacterial Cell Wall Disruptor, 16S Ribosomal RNA Inhibitor, ATP Dependent Clp Protease Proteolytic Subunit Mitochondrial Activator, DNA Gyrase Inhibitor, DNA Topoisomerase IV Inhibitor, RNA Polymerase Inhibitor, and Staphylococcus aureus Bifunctional Autolysin Inhibitor.
-
What are the key routes of administration in the PJI pipeline products market?
The key routes of administration in the PJI pipeline products market are intravenous, intraarticular, parenteral, oral, and topical.
-
What are the key molecule types in the PJI pipeline products market?
The key molecule types in the PJI pipeline products market are biologic, small molecule, recombinant enzyme, monoclonal antibody, and synthetic peptide.
-
Which are the leading companies in the PJI pipeline products market?
Some of the leading companies in the PJI pipeline products market are ContraFect Corp, Adaptive Phage Therapeutics Inc, Arietis Corp, Armata Pharmaceuticals Inc, Integrated BioTherapeutics Inc, Lumobiotics GmbH, Osteal Therapeutics Inc, Peptilogics Inc, and Pherecydes Pharma SA.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Sample Report
Prosthetic Joint Infections Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:
- Assess the relevance of the report
- Evaluate the quality of the report
- Justify the cost
Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.
Related reports
View more Musculoskeletal Disorders reports